Literature DB >> 28135147

Neoadjuvant Therapy in Resectable Pancreatic Cancer: Immortal Time Bias and Its Correction.

Tzu-Yu Lai1, Yu-Wen Hu1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28135147     DOI： 10.1200/JCO.2016.71.2273

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience.

Authors:  Yung-Yeh Su; Yu-Lin Ting; Chih-Jung Wang; Ying-Jui Chao; Ting-Kai Liao; Ping-Jui Su; Nai-Jung Chiang; I-Chuang Liao; Yu-Ting Yu; Yi-Sheng Liu; Hong-Ming Tsai; Yi-Jie Li; Chien-Jui Huang; I-Ting Liu; Hui-Jen Tsai; Chia-Jui Yen; Yan-Shen Shan; Li-Tzong Chen
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

2.  Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.

Authors:  Janick Weberpals; Lina Jansen; Myrthe P P van Herk-Sukel; Josephina G Kuiper; Mieke J Aarts; Pauline A J Vissers; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2017-09-01       Impact factor: 8.082

Review 3.  Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.

Authors:  Han-Xiang Zhan; Jian-Wei Xu; Dong Wu; Zhi-Yang Wu; Lei Wang; San-Yuan Hu; Guang-Yong Zhang
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

4.  Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients.

Authors:  Janick Weberpals; Lina Jansen; Geert Silversmit; Julie Verbeeck; Lydia van der Geest; Pauline Aj Vissers; Vesna Zadnik; Hermann Brenner
Journal:  Clin Epidemiol       Date:  2018-08-30       Impact factor: 4.790

5.  Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases.

Authors:  Si Shi; Xian-Jun Yu
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

Review 6.  Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer-Where Is the Least Harm and Most Benefit?

Authors:  Rupaly Pandé; Keith J Roberts
Journal:  Front Oncol       Date:  2019-10-17       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.